<div><p><b>Background: </b>An outpatient prehabilitation strategy is feasible and effective in improving frailty in liver transplant (LT) candidates. We previously showed that attendance to physical therapy (PT) sessions results in a significant reduction in mortality, but were unable identify the frailty change threshold that yields such benefit.

<div><p><b>Background</b><span style="font-weight: 400;">:</span></p>

<div><p><b>Background:<span> </b>Hepatocellular carcinoma (HCC) recurrence risk after liver transplantation (LT) has been evaluated with different prediction models following pathology explant analysis. The inclusion of alpha-feto protein (AFP) in these models, such as the novel R3-AFP score (1), have significantly improved risk stratification of HCC recurrence post-LT. The SiLVER trial (NCT00355862) evaluated the efficacy of mTOR inhibitors (Sirolimus-Group B) compared to mTOR-free based immunosuppression (Group A) to reduce post-LT HCC recurrence (2).

<div><p><b>Background: </b>Microplastic (MP) is defined as the plastics size less than &lt;5mm. MP accumulates in humans via ingestion. Therefore, the gut-liver axis may be a important to prevent MP accumulation. However, many of the studies focus on the marine organisms and its biological effect and distribution pattern remain to be elucidated in mammals. Therefore, the present study investigates the role of gut-liver axis in protection of hepatic MP accumulation.</p>

<div><p><b>Background:</p> </b><p>Health agencies are waiting for studies with an extended follow-up evaluating whether <em>resolution of MASH without worsening of fibrosis</em> is associated with reduced risk of mortality. This study assessed the impact of histological evolution on long-term survival in MASH patients treated with bariatric surgery.</p>

<div><p><strong><b>Background:</strong> </b>Alcohol-associated liver disease (ALD) is a major public health problem worldwide, and gut microbial dysbiosis is an important contributor to ALD pathogenesis. Our previous study showed that patients with alcohol-associated hepatitis (AH) have increased proportions of mammalian viruses including retroviruses in the fecal virome. However, the role of the gut virome and in particular of endogenous retroviruses (ERVs) for ALD development is unknown.

<div><p><b>Background: </b>Bulevirtide (BLV), a novel hepatitis delta virus (HDV) entry inhibitor, is approved in Europe for treatment of chronic hepatitis D (CHD). In clinical studies, virologic response (VR) was defined as undetectable HDV RNA or ≥2-log₁₀IU/mL decline from baseline (BL). Optimal BLV monotherapy duration for CHD is unknown; it is also unclear whether continued therapy will benefit patients (pts) with early virologic nonresponse (NR) or partial response (PR).

<div><p><b>Background: </b>Contrast-enhanced ultrasound (CEUS) is a promising diagnostic technique for hepatocellular carcinoma (HCC) diagnosis. While EASL HCC guidelines endorse its use in cases of inconclusive CT or MRI based on non-focused studies, the diagnostic potential of CEUS for HCC is not currently recognized by AASLD guidelines. This study aimed to assess the clinical impact of CEUS specifically in cases where liver lesions were indeterminate on MRI.</p>

<div><p><b>Background: </b>Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively impacts prognosis. Response to medical management in AKI is variable, depending on the etiology and severity of the injury. How AKI improvement or response affects liver transplant timing is less clear. We sought to assess the impact of AKI response to treatment on survival and liver transplantation (LT) for patients with cirrhosis waitlisted for LT.</p>

<div><p><b>Background:<strong> </b><span> </span></strong>Hepatic steatosis (HS) and a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of ≥7.5% are associated with increased risk for future cardiovascular events. However, cardiovascular risk of patients with HS at ASCVD&lt;7.5% is not clearly understood.</p>